drugset
drugset / Trial / NCT01209442

Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme

NCT01209442 ↗

Phase 2 Completed 30 enrolled University of Colorado, Denver Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) combining with temozolomide chemotherapy can be safely given with a targeted agent, bevacizumab, and how effective this study treatment will be in controlling your brain tumor.

Timeline

Start
2010-09-16
Primary completion
2014-09-07
Completion
2017-02-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 10 mg/kg —
Subject Temozolomide Small molecule 75 mg/m2 —
Subject Temozolomide Small molecule 150 mg/m2 —
Subject Temozolomide Small molecule 200 mg/m2 —

Indications

glioblastoma